Glypican‐3: a promising biomarker for hepatocellular carcinoma diagnosis and treatment

F Zhou, W Shang, X Yu, J Tian - Medicinal research reviews, 2018 - Wiley Online Library
Liver cancer is the second leading cause of cancer‐related deaths, and hepatocellular
carcinoma (HCC) is the most common type. Therefore, molecular targets are urgently …

Glypican-3: a novel and promising target for the treatment of hepatocellular carcinoma

X Zheng, X Liu, Y Lei, G Wang, M Liu - Frontiers in oncology, 2022 - frontiersin.org
Glypican-3 (GPC3) is a membrane-associated proteoglycan that is specifically up-regulated
in hepatocellular carcinoma (HCC) although rarely or not expressed in normal liver tissues …

Redirecting T cells to glypican-3 with 4-1BB zeta chimeric antigen receptors results in Th1 polarization and potent antitumor activity

W Li, L Guo, P Rathi, E Marinova, X Gao… - Human gene …, 2017 - liebertpub.com
T cells engineered to express CD19-specific chimeric antigen receptors (CARs) have shown
breakthrough clinical successes in patients with B-cell lymphoid malignancies. However …

Normal alpha-fetoprotein hepatocellular carcinoma: are they really normal?

CW Lee, HI Tsai, WC Lee, SW Huang, CY Lin… - Journal of clinical …, 2019 - mdpi.com
Introduction: serum alpha-fetoprotein (AFP) was routinely employed as a tumor marker for
screening, diagnosis, and treatment follow-up of hepatocellular carcinoma (HCC). However …

Practical immunohistochemistry in neoplastic pathology of the gastrointestinal tract, liver, biliary tract, and pancreas

HL Wang, CJ Kim, J Koo, W Zhou… - … of pathology & …, 2017 - meridian.allenpress.com
Context.—Immunomarkers with diagnostic, therapeutic, or prognostic values have been
increasingly used to maximize the benefits of clinical management of patients with …

Imaging the expression of glypican-3 in hepatocellular carcinoma by PET

Z Wang, YJ Han, S Huang, M Wang, WL Zhou, HS Li… - Amino Acids, 2018 - Springer
Abstract The glypican-3 (GPC3) receptor is overexpressed in hepatocellular carcinoma
(HCC) and is a potential diagnostic and therapeutic target. GPC3-targeted molecular …

CRISPR‐induced exon skipping of β‐catenin reveals tumorigenic mutants driving distinct subtypes of liver cancer

H Mou, O Eskiocak, KA Özler, M Gorman… - The Journal of …, 2023 - Wiley Online Library
CRISPR/Cas9‐driven cancer modeling studies are based on the disruption of tumor
suppressor genes by small insertions or deletions (indels) that lead to frame‐shift mutations …

[HTML][HTML] Uncovering essential anesthetics-induced exosomal miRNAs related to hepatocellular carcinoma progression: a bioinformatic investigation

N Huang, J Fang, F Du, J Zhou, Y Li… - BMC Medical …, 2024 - ncbi.nlm.nih.gov
Background Anesthetic drugs may alter exosomal microRNA (miRNA) contents and mediate
cancer progression and tumor microenvironment remodeling. Our study aims to explore how …

Alternative biomarkers to predict tumor biology in hepatocellular carcinoma

P Abreu, R Ferreira, V Mineli, MA Ribeiro… - Anticancer …, 2020 - ar.iiarjournals.org
Hepatocellular carcinoma (HCC) is the most frequent primary malignant liver tumor, with
more than 800,000 new cases diagnosed each year and with high mortality, ranking fourth …

[HTML][HTML] Ancillary tests for hepatobiliary neoplasms: what we know and what we need to know

SL Zhang, HL Wang - Human Pathology, 2023 - Elsevier
Ancillary tests are commonly used in the surgical pathology setting for diagnosing
challenging neoplastic diseases of the liver and biliary tract, while histology and clinical …